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Aim of database: The Danish Neuro-Oncology Registry (DNOR) was established by the Danish 
Neuro-Oncology Group as a national clinical database. It was established for the purpose of sup-
porting research and development in adult patients with primary brain tumors in Denmark.
Study population: DNOR has registered clinical data on diagnostics and treatment of all 
adult patients diagnosed with glioma since January 1, 2009, which numbers approximately 
400 patients each year.
Main variables: The database contains information about symptoms, presurgical magnetic 
resonance imaging (MRI) characteristics, performance status, surgical procedures, residual 
tumor on postsurgical MRI, postsurgical complications, diagnostic and histology codes, radio-
therapy, and chemotherapy.
Descriptive data: DNOR publishes annual reports on descriptive data. During the period of 
registration, postoperative MRI is performed in a higher proportion of the patients (Indicator II), 
and a higher proportion of patients have no residual tumor after surgical resection of the primary 
tumor (Indicator IV). Further data are available in the annual reports. The indicators reflect 
only minor elements of handling brain tumor patients. Another advantage of reporting indica-
tors is the related multidisciplinary discussions giving a better understanding of what actually 
is going on, thereby facilitating the work on adjusting the national guidelines in the Danish 
Neuro-Oncology Group.
Conclusion: The establishment of DNOR has optimized the quality in handling primary brain 
tumor patients in Denmark by reporting indicators and facilitating a better multidisciplinary 
collaboration at a national level. DNOR provides a valuable resource for research.
Keywords: brain neoplasms, brain cancer, glioma, clinical quality indicators
Aim of database
The Danish Neuro-Oncology Registry (DNOR) is a national clinical database collect-
ing data on diagnostics and treatments in adult patients with primary brain tumors in 
Denmark.1 It was established with the purpose of supporting clinical development and 
research in this patient group.
The Danish Neuro-Oncology Group (DNOG) is developing and implementing 
national guidelines on treating adult brain tumor patients in Denmark.2 By the supply 
of data from DNOR, the discussions in DNOG are facilitated and performed on a 
more evidence-based background. A few key clinical quality indicators are selected in 
DNOR, giving each clinical department the opportunity to compare its own results to 
predefined standards and to reported national levels, and to follow-up on time trends 
of its own results.
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Study population
In Denmark (5.5 million inhabitants), approximately 1,550 
patients are diagnosed with brain tumor each year and the 
incidence is increasing. Brain tumor diagnoses are classified 
by the International Classification of Diseases (ICD) codes 
and the Systematized Nomenclature of Medicine Morphol-
ogy codes.3,4 The ICD-10 codes may be grouped into the 
following entities (Table 1): cerebral tumors, meningioma, 
sellae tumors, pineal tumors, neurinoma, and spinal tumors. 
Patients in each group are handled in different ways clinically, 
and accordingly, different data need to be registered. There 
is an ongoing work to include patients from all groups, but 
until now, the primary focus has been on glioma patients who 
make up the major part of adult brain tumor patients. These 
patients are identified by the M-codes given in the first row 
of Table 1. DNOR has included all patients diagnosed with 
glioma (excluding ependymoma) since January 1, 2009, 
which numbers approximately 400 patients each year.
Main variables
Data are registered in four different forms linked in a hier-
archical data model (Figure 1). The forms including data 
on diagnostic and surgery are entered by the Department of 
Neurosurgery and the forms including data on chemotherapy 
and radiotherapy are entered by the Department of Oncology. 
The data are transferred to an analytical database which can 
describe the clinical course of the patients and administrative 
issues. Using the unique ten-digit code given to all Danish citi-
zens, the analytical database is further linked to the Danish Civil 
Registration System5 to obtain residence and vital status.
Data contain information about symptoms, presurgi-
cal magnetic resonance imaging (MRI) characteristics, 
performance status, surgical procedures, residual tumor on 
postsurgical MRI, postsurgical complications, ICD-10 codes, 
Systematized Nomenclature of Medicine Morphology codes, 
radiotherapy, and chemotherapy.
Table 2 shows the indicators used in DNOR. There are two 
process and five results indicators describing survival, early post-
operative MRI, surgical qualification, extent of surgical resec-
tion, postsurgical mortality, radiotherapy, and chemotherapy.
From 2009 to 2014, clinical data on 2,238 patients have 
been reported in DNOR, representing 92% of all cases iden-
tified in the central registries using the relevant diagnostic 
codes presented in the first row of Table 1. In approximately 
5% of the included patients, only oncological data were 
reported, while basic diagnostic and surgical data were 
missing. From 2015, the DNOR has been using algorithms 
from the standardized platform for the Danish Clinical 
Table 1 List of relevant iCD-10 codes for DNOR and SNOMED 
M-codes, which defines the inclusion criteria for calculation of 
indicators in DNOR
Groups ICD-10 codes SNOMED 
M-codes
Cerebral tumors DD33.0–33.2 
DD33.7 
DD33.9 
DD43.0–43.2 
DD43.7+9  
DC71.0–71.9 
DC72.8 
DC72.9
M93813, 
M93823, 
M93841, 
M93853, 
M94003, 
M94013, 
M94113, 
M94213, 
M94243, 
M94253, 
M94403, 
M94423, 
M94503, 
M94513
Meningioma DD32.0–32.9 
DD42.0–42.9 
DC70.0–9
Sellae tumors DD35.2 
DD35.3 
DD44.3 
DD44.4 
DD75.1 
DD75.2
Pineal tumors DD35.4 
DD44.5 
DD75.3
Neurinoma DD33.3 
DD43.3 
DC72.2–72.5
Spinal tumors DD33.4 
DD43.4 
DC72.0–72.1
Abbreviations: DNOR, Danish Neuro-Oncology Registry; iCD, international 
Classification of Diseases; M, morphology; SNOMED, Systematized Nomenclature 
of Medicine.
Cancer Registries,6 which will optimize the completeness of 
the identification of patients with brain tumors in DNOR.
Follow-up
Table 3 shows the results of clinical indicators from 2010 to 
2014. There is a trend that postoperative MRI is performed in 
a higher proportion of patients (Indicator II) and another trend 
that a higher proportion of patients have no residual tumor after 
surgical resection of the primary tumor (Indicator IV). Further 
data are available in the annual reports from DNOR.7
Examples of research
DNOR provides an important source of clinical data for 
scientific investigations. The scientific utility demands 
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Patient
1:N  Data from the clinical course of the patient
1:1  Diagnostic data
1:N  Surgery data
1:N  Chemotherapy data
1:N  Radiotherapy data
Figure 1 Data model of the Danish Neuro-Oncology Registry.
Table 2 Clinical quality indicators used in the Danish Neuro-
Oncology Registry
Number Descriptions Standards
ia Proportion of patients who are alive 1 year 
after surgery out of all patients in whom the 
histological diagnosis is glioblastoma
$50%
ib Proportion of patients who are alive 2 years 
after surgery out of all patients in whom the 
histological diagnosis is glioblastoma
$15%
ii Proportion of patients who have undergone 
postoperative MRi no later than the 
third day after primary surgery out of all 
patients who have undergone resection 
and have contrast-enhancing tumor 
(ie, suspected high-grade glioma) prior to 
resection
$90%
iii Proportion of operations conducted by or 
supervised by a specialist in neurosurgery 
out of all operations both primary and at 
progression
$95%
iv Proportion of patients with no measurable 
residual tumor demonstrated by postoperative 
MRi performed after primary surgery out 
of all primarily diagnosed patients, where 
the histological diagnosis is glioblastoma (ie, 
denominator includes also those patients with 
only performed biopsy or where control MRi 
scan is not available)
$20% and  
#70%
v Proportion of patients alive more than 30 
days after surgery out of all patients who have 
undergone primary surgery for gliomas
$95%
vi Proportion of patients finishing focal high-
dose radiation therapy as planned out of all 
patients starting this treatment and where the 
histological diagnosis is glioblastoma
$90%
vii Proportion of patients finishing concomitant 
chemoradiotherapy with temozolomide 
as planned out of all patients starting this 
treatment and where the histological diagnosis 
is glioblastoma
$85%
Abbreviation: MRi, magnetic resonance imaging. T
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completeness and validity of data. Hence, there is an ongoing 
research project with the purpose of evaluating the complete-
ness of data as well as data validity. Furthermore, several 
epidemiological studies based on data from the initial 6 years 
from 2009 to 2014 are in progress. Generally, DNOR provides 
the opportunity for clinical research in glioma patients in 
a population-based setting. The possibility to link to other 
Danish national registries such as the Danish Civil Registra-
tion System,5 the Danish National Patient Registry,8 and the 
Danish National Pathology Registry9 further strengthens the 
research potential.
Administrative issues and funding
DNOR was established under the auspices of DNOG, 
which is the Danish Multidisciplinary Cancer Group on 
primary brain tumors in adult patients. DNOG members 
are appointed by the relevant member society under the 
Organization of Danish Medical Societies including neu-
rosurgery, medical and radiation oncology, neurology, 
neuroradiology, pathology, and nuclear medicine. DNOR is 
financially supported by the Danish health care authorities 
through a national quality program organized in the Dan-
ish Clinical Registries.10 Also, there is technical support 
from the Registry Support Centre of Epidemiology and 
Biostatistics, South.
Conclusion
The establishment of DNOR has optimized the quality 
in handling primary brain tumor patients in Denmark by 
introducing clinical quality indicators and facilitating a 
better multidisciplinary collaboration at a national level. 
DNOR variables and indicators are selected by clinicians 
for the discussion of quality on a more reliable background 
on selected topics. This discussion takes place in DNOG 
with the possibility of simultaneous adjustment in national 
guidelines to optimize the implementation of procedures 
in clinical practice. Also, DNOR data are a useful research 
resource for the future.
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